Physician profile
Surmeet Bedi
NPI 1710911334
$4,290.38
in general payments reported to CMS, 2019-2025
28 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $220 · 2021: $711 · 2022: $588 · 2023: $442 · 2024: $589 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,896 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,895.52 |
| Education | $159.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $502.69 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $421.91 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $415.53 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $413.76 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $386.40 | 2019-2023 | Korsuva, Veltassa |
| Opko Pharmaceuticals, LLC | $336.96 | 2019-2025 | Rayaldee |
| Akebia Therapeutics INC | $277.65 | 2019-2024 | Auryxia, Vafseo |
| Otsuka America Pharmaceutical, INC. | $275.23 | 2019-2025 | Jynarque |
| Mallinckrodt Enterprises LLC | $202.60 | 2019 | |
| Novartis Pharmaceuticals Corporation | $163.69 | 2023-2025 | |
| Amgen INC. | $151.20 | 2019-2025 | Tavneos, Krystexxa |
| Ardelyx, INC. | $141.35 | 2024-2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $129.25 | 2019-2025 | Velphoro |
| Nxstage Medical, INC. | $71.93 | 2019 | |
| Kyowa Kirin, INC. | $58.57 | 2023-2025 | Crysvita |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $43.28 | 2022-2025 | Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $40.61 | 2019-2023 | Gattex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.80 | 2024-2025 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $37.15 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $34.49 | 2020-2021 | |
| Aurinia Pharma U.S., INC. | $25.20 | 2022 | |
| Travere Therapeutics, INC. | $22.40 | 2024 | |
| Daiichi Sankyo INC. | $20.49 | 2019 | |
| Mallinckrodt Hospital Products INC. | $19.85 | 2020 | |
| Pharmacosmos Therapeutics INC. | $18.05 | 2024 | Monoferric |
| Lilly USA, LLC | $15.10 | 2023 | Jardiance |
| Renalytix Ai, INC. | $13.44 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surmeet Bedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.